Your browser doesn't support javascript.
loading
Cholinergic deficiency in Parkinson's disease patients with visual hallucinations.
d'Angremont, Emile; van der Zee, Sygrid; Slingerland, Sofie; Slomp, Anne C; de Vries, Erik F J; van Laar, Teus; Sommer, Iris E.
Afiliación
  • d'Angremont E; Department of Psychiatry, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.
  • van der Zee S; Department of Neurology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.
  • Slingerland S; Department of Neurology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.
  • Slomp AC; Department of Neurology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.
  • de Vries EFJ; Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.
  • van Laar T; Department of Neurology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.
  • Sommer IE; Department of Psychiatry, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.
Brain ; 2024 Jun 12.
Article en En | MEDLINE | ID: mdl-38864492
ABSTRACT
Visual hallucinations (VH) can increase the burden of disease for both patients with Parkinson's disease (PD) and their caregivers. Multiple neurotransmitters have been implicated in the neuropathology of VH, which provide targets for treatment and prevention. In this study, we assessed the association between cholinergic denervation and VH in PD in vivo, using PET imaging of the cholinergic system. A total of 38 PD patients participated in this study. A group of 10 healthy subjects, matched for age, sex and education, was included for comparison. None of the participants used cholinergic drugs. Thirteen patients who had experienced VH in the past month (VH+) were compared to 20 patients who had never experienced VH in their lives (VH-). Cholinergic system integrity was assessed with PET imaging using [18F]fluoroethoxybenzovesamicol ([18F]FEOBV) as the tracer. We assessed the differences in tracer uptake between groups by cluster-based analysis and by analysis of predefined regions of interest (ROIs) consisting of the ventral visual stream, the dorsal attentional network, the ventral attentional network and the lateral geniculate nucleus and mediodorsal nucleus of the thalamus. The PD group (n=38) showed an extensive pattern of decreased tracer uptake throughout the brain, compared to the controls (n=10). Within the PD group, the VH+ group (n=13) showed a cluster of decreased tracer uptake compared to the VH- group (n=20), which covered most of the left ventral visual stream and extended towards superior temporal areas. These results were mirrored in the ROI-based analysis, where the VH+ group showed the strongest deficits in the left inferior temporal gyrus and the left superior temporal gyrus, compared to the VH- group. VH in PD are associated with a marked cholinergic deficiency in the left ventral visual stream and the left superior temporal lobe, in addition to an extensive global cholinergic denervation in the general PD population.
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2024 Tipo del documento: Article